ClinicalTrials.gg
RecruitingNCT07050537Updated Jun 1, 2026

A Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology

An interventional study of Constant oxygen concentration protocols in embryo culture and Sequential oxygen concentration protocols in embryo culture in Fertility Issues, Blastocyst IVF and Embryo Culture, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 6 sites in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2025, registered Jun 2025).
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
980
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Infertility with a site in China — 38 open to participants now, 41 under way, 5 of them phase 3. Infertility · China.

Planned enrollment
15th of 107
980 · median 248
Started
2025
with 13 others
No phase
65 of 139
22 open now
Primary completion
2027-03
later than 18 of 40 live
Registered
122nd of 139
by date

Among the 139 studies in Infertility with a site in China, this one is the 15th largest by planned enrollment of the 107 interventional ones that give a count, is one of 14 that started in 2025, is one of 65 with no phase, reaches primary completion later than 18 of the 40 other live ones, and was the 122nd registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

38 of the 139 studies in Infertility with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 20 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Infertility with a site in China, or all of them as a file.
02

Study summary

To evaluate whether there were significant differences in the effects of constant (5%) versus sequential (5%-2%) oxygen concentration protocols in embryo culture on term live birth rates.

This study will be conducted in five centers including the Clinical Center of Reproductive Medicine, First Affiliated Hospital of Nanjing Medical Universit. 980 women who wish to undergo blastocyst transplantation will be included in the study.

The study data will be analyzed statistically.

Read the detailed description

While blastocyst transfer has been shown to improve live birth rates, concerns exist regarding potential telomere shortening in offspring, which is associated with premature aging and various health issues. Our previous study further explores the role of oxygen tension in telomere length regulation, identifying hypoxia-inducible factor 1α (Hif1α) degradation as a key factor. Based on these findings, the study proposes a prospective, randomized controlled clinical trial comparing constant (5%) versus sequential (5%-2%) oxygen concentration protocols in embryo culture to assess their impact on term live birth rates and offspring telomere length.

This study will be conducted in five centers including the Clinical Center of Reproductive Medicine, First Affiliated Hospital of Nanjing Medical Universit. 980 women who wish to undergo blastocyst transplantation will be included in the study.

Female infertile patients who consent to blastocyst transfer will be considered for inclusion in the study. Patients will be randomly assigned to a constant (5%) or sequential (5%-2%) oxygen concentration protocols in embryo culture. This study will record live birth rates, perinatal and perinatal complications, and offspring health status of women in both groups of embryo culture regimens to assess the effects of different embryo culture regimens on term live birth rates and offspring health.

03

Conditions studied

  • Fertility Issues
  • Blastocyst IVF
  • Embryo Culture

Browse trials for

Keywords

  • Blastocyst IVF
  • Fertility
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female: age ≥20 and ≤40 years, male: age ≥20 and ≤50 years;
  2. Proposed 1st or 2nd cycle of IVF or ICSI fertilization;
  3. ≥ 4 transferable embryos at oocyte stage.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of abnormal uterine cavity morphology (confirmed by 3D ultrasound or hysteroscopy), including uterine malformations (mediastinal uterus, unicornuate uterus, bicornuate uterus), submucosal uterine fibroids, or uterine adhesions;
  2. Patients who are proposed to undergo IVM;
  3. Patients who are proposed to undergo PGD/ PGS;
  4. Patients with untreated severe hydrosalpinx (confirmed by ultrasound or HSG);
  5. Patients with a history of recurrent miscarriage (2 or more previous pregnancy losses, excluding biochemical pregnancies);
  6. Patients who plan to freeze whole embryos and are unable to complete a single embryo transfer within six months;
  7. Patients with to assisted reproductive technology and pregnancy, or suffering from diseases that have a definite effect on pregnancy: including uncontrolled hypertension, heart disease with definite symptoms, uncontrolled diabetes, undefined diagnosis of liver or kidney disease or liver or kidney insufficiency, severe anemia, history of previous venous thrombosis, pulmonary embolism or cerebrovascular events, history of malignant tumors, suspected malignant tumors, and undiagnosed abnormal uterine bleeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
980 participants (estimated)

Study arms

  • Placebo comparator
    Constant (5%) oxygen concentration protocols in embryo culture

    Patients randomly assigned to use constant (5%) oxygen concentration protocols in embryo culture

    Procedure: Constant oxygen concentration protocols in embryo culture

  • Experimental
    Sequential (5%-2%) oxygen concentration protocols in embryo culture

    Patients randomly assigned to use Sequential (5%-2%) oxygen concentration protocols in embryo culture

    Procedure: Sequential oxygen concentration protocols in embryo culture

Interventions

  • ProcedureConstant oxygen concentration protocols in embryo culture

    Participants were randomly assigned to constant (5%) oxygen concentration group and received different blastocyst culture protocols.

  • ProcedureSequential oxygen concentration protocols in embryo culture

    Participants were randomly assigned to sequential (5%-2%) oxygen concentration group and received different blastocyst culture protocols.

06

What researchers measure

Primary outcomes

  1. Term live births

    Full-term healthy live birth rate for all patients

    Time frame: 3 years

Secondary outcomes

  1. Offspring health (Peripheral blood telomere length)

    Peripheral blood telomere length in all live-born offspring

    Time frame: 3 years

  2. Clinical pregnancy rate

    Clinical pregnancy rate for all transfer cycles

    Time frame: 3 years

  3. Ectopic pregnancy rate

    Ectopic pregnancy rate for all transfer cycles

    Time frame: 3 years

  4. Implantation rate

    Implantation rate per transfer cycle

    Time frame: 3 years

  5. Miscarriage rate

    Miscarriage rate per transfer cycle

    Time frame: 3 years

07

Study locations

6 of 6 sites recruiting
08

References and documents

Publications

  • De Munck N, Janssens R, Segers I, Tournaye H, Van de Velde H, Verheyen G. Influence of ultra-low oxygen (2%) tension on in-vitro human embryo development. Hum Reprod. 2019 Feb 1;34(2):228-234. doi: 10.1093/humrep/dey370. PubMed 30576441 ↗
  • Kaser DJ, Bogale B, Sarda V, Farland LV, Williams PL, Racowsky C. Randomized controlled trial of low (5%) versus ultralow (2%) oxygen for extended culture using bipronucleate and tripronucleate human preimplantation embryos. Fertil Steril. 2018 Jun;109(6):1030-1037.e2. doi: 10.1016/j.fertnstert.2018.02.119. PubMed 29935641 ↗
  • Brouillet S, Baron C, Barry F, Andreeva A, Haouzi D, Gala A, Ferrieres-Hoa A, Loup V, Anahory T, Ranisavljevic N, Gaspari L, Hamamah S. Biphasic (5-2%) oxygen concentration strategy significantly improves the usable blastocyst and cumulative live birth rates in in vitro fertilization. Sci Rep. 2021 Nov 17;11(1):22461. doi: 10.1038/s41598-021-01782-6. PubMed 34789773 ↗
  • Chakravarti D, LaBella KA, DePinho RA. Telomeres: history, health, and hallmarks of aging. Cell. 2021 Jan 21;184(2):306-322. doi: 10.1016/j.cell.2020.12.028. Epub 2021 Jan 14. PubMed 33450206 ↗
  • Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023 Jan 19;186(2):243-278. doi: 10.1016/j.cell.2022.11.001. Epub 2023 Jan 3. PubMed 36599349 ↗
  • Wang C, Gu Y, Zhou J, Zang J, Ling X, Li H, Hu L, Xu B, Zhang B, Qin N, Lv H, Duan W, Jiang Y, He Y, Jiang T, Chen C, Han X, Zhou K, Xu B, Liu X, Tao S, Jiang Y, Du J, Dai J, Diao F, Lu C, Guo X, Huo R, Liu J, Lin Y, Xia Y, Jin G, Ma H, Shen H, Hu Z. Leukocyte telomere length in children born following blastocyst-stage embryo transfer. Nat Med. 2022 Dec;28(12):2646-2653. doi: 10.1038/s41591-022-02108-3. Epub 2022 Dec 15. PubMed 36522605 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

Of 385 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 24 months is close to that.

Counting every sponsor, half of 415 studies reached it within 24 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 3, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07050537
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Mar 1, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Xiang Ma
Contact
sxmaxiang@126.com
+86 18001581878
Haofeng Wang
Contact
haofengwang@stu.njmu.edu.cn
+86 18018387209

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion